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Abstract: Pagoclone is a novel cyclopyrrolone that acts as a partial GABAA receptor agonist. 
Preclinical studies suggest that pagoclone may have clinical utility as an anxiolytic agent, as 
well as a reduced incidence of side-effects. The present study was conducted to determine 
whether pagoclone would affect healthy individuals’ performances on neuropsychological 
measures as a function of dose within the projected therapeutic range. Twelve healthy adult 
subjects were randomly assigned to dosage groups in a 3-way crossover study. Participants 
were administered neuropsychological measures six hours following dosing on Day 1 and Day 
6 of administration of the drug. Dose effects were noted on measures of alertness, learning, 
and memory and movement time. Signiﬁ  cant effects were also noted on measures of alertness, 
learning and memory, information processing and psychomotor speed. Overall, the results of 
this small, preliminary study do not support a ﬁ  nding of behavioral toxicity for these doses of 
pagoclone. Rather, a pattern was found of transient and mild negative effects on learning and 
memory scores at the highest dose administered, though these changes were small and no longer 
evident by the sixth day of use.
Keywords: pagoclone, cyclopyrrolone, neuropsychological, memory, generalized anxiety 
disorder
Introduction
Behavioral toxicity refers to the extent to which a drug affects an individual’s ability 
to perform the psychomotor and cognitive tasks of everyday life (Ramaekers 1998). 
At a signiﬁ  cant level, behavioral toxicity may impair cognitive and psychomotor abili-
ties to such an extent that the improvement of symptoms of psychological disorders is 
hindered. Generalized Anxiety Disorder (GAD) and Panic Disorder (PD) are among 
the most prevalent of psychiatric disorders. In the United States, as many as 5% of 
people will experience GAD and 3.5% will experience PD over the course of their 
lifetimes (American Psychiatric Association 2000). Agents currently used to treat 
GAD/PD include benzodiazepines, hypnotics, and anxiolytics. These medications are 
known to have variable, negative effects on memory, learning, motor function and 
cognition (Rickels and Rynn 2002). Thus, development of effective agents to treat 
GAD/PD with minimal negative cognitive effects is crucial.
Pagoclone (CI-1043, IP456) is a novel cyclopyrrolone that pharmacologically is a 
non selective partial GABAA receptor agonist (Lingford-Hughes et al 2005). A main 
feature of partial agonists is the limited degree to which they open the ion channel. 
In comparison, full agonists afford complete opening, allowing uninhibited inﬂ  ux of 
Ca+ ions while occupying a relative low (~5%) percentage of receptors. Preclinical 
and clinical studies suggest that pagoclone may have clinical utility as an anxiolytic 
agent in the dose range of 0.15 mg BID to 0.6 mg BID, as well as reduced incidence 
of side-effects when compared to other conventional anxiolytics, speciﬁ  cally diazepam 
(Donevan et al 2000; Sandford et al 2001; Atack 2005).Neuropsychiatric Disease and Treatment 2008:4(1) 278
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Pagoclone differs from benzodiazepines in that it does not 
emit a full electrophysiological response to GABA stimula-
tion in vitro. Adverse events appear to be dose-related, with 
the most common side-effects reported as somnolence, diz-
ziness, headache, asthenia, and lethargy, though cognitive 
effects have not yet been tested. In comparison, Zopiclone 
is also a partial GABA agonist cyclopyrrolone. Subtle and 
transient effects on memory and attention have previously 
been reported with zopiclone (Allain et al 1995; Stip et al 
1999; Hemmeter et al 2000; Silva et al 2003).
The present study was conducted to determine whether 
pagoclone would affect a healthy individual’s performance 
on neuropsychological measures of learning, memory, motor 
function and cognition, as a function of dose within the 
projected therapeutic range.
Materials and methods
Subjects
A total of 12 healthy subjects (ﬁ  ve men, seven women), 
aged 18–55 years gave their Internal Review Board (IRB) 
approved written consent after study procedures and possible 
side effects were explained to them. Participants were paid 
for their time. No signiﬁ  cant differences for age were found 
across gender (Mean age men = 36.0, SD = 8.6; Mean age 
women = 32.6, SD = 9.8). Exclusion criteria were: 1) use of 
any central nervous system active or other potentially inter-
fering medications during a 14-day period before the start of 
the study; 2) donation of a unit of blood within 30 days of the 
start of the study; 3) sexually active women not surgically 
sterile or using a reliable method of birth control; 4) history 
of signiﬁ  cant adverse reaction to benzodiazepines or other 
anti-anxiety medications; 5) any clinically signiﬁ  cant medical 
or psychiatric disorder; and 6) signiﬁ  cant urine concentration 
of any drug that could interfere with the study.
Neuropsychological measures
Sleepiness/alertness
The Stanford Sleepiness Scale (Hoddes et al 1972) is a 
self-report, general measure of sleepiness consisting of a 
single rating based on seven statements with a higher score 
indicating increased sleepiness.
Learning/memory
Measures of learning and memory were derived from the 
Buschke Selective Reminding Test (BSRT) (Buschke and 
Fuld 1974). This test is a verbal word list learning task 
consisting of 6 trials of 24 words using selective reminding 
procedures. Subjects were asked to recall as many of the 
words from the word list as they could in any order. Each 
subsequent learning trial involved the selective presentation 
of only those items that were not recalled on the immediately 
preceding trial, but subjects were again asked to recall the 
whole list. The BSRT distinguishes between short-term 
and long-term components of memory by measuring recall 
of items that were not presented on a given trial. The fol-
lowing scores were measured from the BSRT: Immediate 
Recall (total number of words correctly remembered across 
all trails), Long Term Storage (LTS; total words recalled 
without the need for reminding), and Delayed Recall (total 
words recalled after a delay of approximately 20 minutes). 
Equivalent, alternate forms were available for this test.
Psychomotor speed
The Motor Screen subtest of the Cambridge Neuropsycho-
logical Test Automated Battery (CANTAB) (Morris 1987) 
represents a measure of visuomotor tracking requiring a 
subject to touch “X’s” that randomly appear on a computer 
screen as quickly as possible. The primary score from this 
measure was the response time latency.
Information processing efﬁ  ciency
Efﬁ  ciency in information processing and sustained vigilance 
were measured with the Rapid Visual Information Processing 
task (RVP) from the computerized CANTAB battery. 
Subjects were given a two-minute training session to orient 
them to this task. In the four-minute test portion of this 
task, subjects were presented with three sequences of digits 
(eg, 3*5*7, 2*4*6, 4*6*8) and asked to press a button when 
the third digit of any of the target sequences appeared in a 
box on the screen. The target sequences remained on the 
screen to help subjects to remember them. Two primary 
scores were utilized from this measure: A' and Mean Latency. 
A' is a signal detection measure of sensitivity to the target 
regardless of the tendency to respond. Mean Latency reﬂ  ects 
average response time for correct responses. Parallel forms 
were available for this test measure.
Simple/complex attention
Both simple (SRT; single target location) and choice (CRT, 
ﬁ  ve target locations) reaction time tasks were administered to 
subjects with the computerized CANTAB system. In simple 
reaction time tests, subjects were asked to press a key as soon 
as they saw anything at all appear on the screen. In choice 
reaction time tests, subjects were asked to press a key only 
after they saw a speciﬁ  c visual stimulus appear on the screen. 
For each task, both Reaction Time (speed with which the 
subject releases a press pad in response to a stimulus) and Neuropsychiatric Disease and Treatment 2008:4(1) 279
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Movement Time (time taken to touch the stimulus after the 
press pad has been released) were measured in milliseconds. 
Parallel forms were also available for this test.
Psychomotor problem solving
The Digit Symbol (Wechsler 1981) test is a code substitution 
task that measures processing speed and efﬁ  ciency in psy-
chomotor problem solving. The Digit Symbol test consists of 
7 rows of small blank squares, each paired with a randomly 
assigned number from 1 to 9. At the top of the page is a key 
that pairs each number with a different nonsense symbol. 
Subjects were required to ﬁ  ll in the blank spaces with the 
corresponding symbol as quickly as possible for 90 seconds. 
Parallel forms were also available for this test.
Study design
Subjects were entered into an open label (assessor blind), ran-
domized, multiple-dose, 3-way crossover, pharmacokinetic 
dose-proportionality study. They received 0.15 mg (low), 
0.30 mg (medium), or 0.60 mg (high) doses of pagoclone 
every 12 hours for seven days with a seven-day washout 
between periods. Subjects were randomly assigned to one 
of three groups as they were screened for study inclusion. 
Groups differed by the order the drug doses were adminis-
tered. Although capsule size varied, subjects were blinded 
to speciﬁ  c dosage. As subjects were randomly assigned, no 
effort was made to distribute gender evenly across groups, 
though two groups did each have two men and women and 
the third had three females and one male.
Three practice test sessions were administered prior to the 
baseline evaluations. Subjects were then tested at Baseline 
(the day prior to administration of the drug), Day 1, and Day 
6, in order to examine both acute and steady state effects. 
Neuropsychological testing was conducted approximately six 
hours after dosing on Days 1 and 6. Testing was completed 
at the same time of day for all evaluations (excluding prac-
tice). Six hours after dosing was close to the tmax for both 
pagoclone and the metabolite. Four trained examiners (two 
primary and two backup) completed the cognitive testing 
for the study. Examiners were blind with respect to treat-
ment condition. Alternate test forms were pseudo-randomly 
assigned to each subject’s testing sessions, such that no one 
subject saw the same form twice.
Data analysis
Change scores, calculated as Day 1 minus baseline and Day 
6 minus baseline, were computed for all variables of interest. 
Data were analyzed using individual repeated measures 
ANCOVA through SAS (PROC MIXED), using Least 
Squares Means. Analyses were done on 12 variables. Given 
the preliminary nature of this study, no attempt was made 
to adjust for the alpha level. Age was entered as a covariate 
and adjusted means from the ANCOVA are presented in this 
paper. The covariate, age, was found to be signiﬁ  cant only for 
the three learning and memory measures (all p   0.05). Main 
effects were calculated for the variables of Gender (between 
effect), Dose (within effect). Day (within effect) and Order 
(between effect). Doses were coded as Low (0.15 mg), 
Medium (0.30 mg), or High (0.60 mg). Day was either Day 
1 or Day 6. Order was designated as Order 1 (0.15 mg, 0.30 mg, 
0.60 mg), Order 2 (0.60 mg, 0.15 mg, 0.30 mg), and Order 3 
(0.30 mg, 0.60 mg, 0.15 mg).
Because this was primarily a preliminary pharmacoki-
netic study, it was decided that complete randomization was 
not necessary. Thus, three of six possible orders were used. 
Primary comparisons of interest were the overall changes in 
neuropsychological performance for Gender, Day, Order, 
and Dose, represented by main effects for each variable, 
and the interaction of Dose by Day to test for differential 
patterns of performance on each dose across the test days. 
Differences for least square means were examined for post-
hoc comparisons.
Results
Across all variables of interest, no signiﬁ  cant ﬁ  ndings 
were noted for the main effects of Order or Gender, or for 
the Dose by Day interaction. The results of analyses for the 
change scores for the main effects for both Day (Table 1) 
and Dose (Table 2) are reported in the sections below.
Sleepiness/alertness
On the Stanford Sleepiness scale, there were main effects for 
Day (F = 7.82, p = 0.007) and for Dose (F = 4.20, p = 0.021). 
Regardless of dose, subjects reported having a signiﬁ  cantly 
greater increase in fatigue from baseline to Day 1 than from 
baseline to Day 6. The medium dose was associated with 
signiﬁ  cantly higher self-report of fatigue than the lowest dose 
(p   0.006). Average change scores for both the Dose and 
Day main effects, however, did not exceed one point.
Learning/memory
Three scores were analyzed from the Buschke Selective 
Reminding Test (ie, Immediate Recall, LTS, and Delayed 
Recall). A main effect for Day was noted on Delayed 
Recall (F = 811, p = 0.006) and LTS (F = 4.73, p = 0.035). 
There was also a main effect for Dose for Immediate Recall Neuropsychiatric Disease and Treatment 2008:4(1) 280
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(F = 4.68, p = 0.014), LTS (F = 5.34, p = 0.008), and 
Delayed Recall (F = 3.71, p = 0.032). An inspection of the 
BSRT variables on Table 1 reﬂ  ects a consistent pattern of 
changes in performance essentially localized to Day 1, with 
Day 6 change scores essentially suggesting no change from 
baseline, hence a return to baseline functioning. Regard-
ing Dose effects (Table 2), the decline from baseline in 
Immediate Recall was signiﬁ  cantly greater for the high 
dose as compared to the low dose. For the LTS score, sig-
niﬁ  cantly greater declines from baseline were noted on both 
the medium and high doses as compared to the low dose. 
For the Delayed Recall score, no change score differences 
were found between the Low Dose and the Medium Dose, 
though declines on the High Dose were signiﬁ  cantly greater 
than the other two doses. Overall, there was a generally 
consistent pattern of no change to some improvement across 
change scores for the low dose, with declines in performance 
from baseline evident for the other two doses.
Psychomotor speed
Motor speed was measured with the Response Latency score 
from the Motor Screening task of the CANTAB battery. 
Table 1 Change from baseline for all subjects: main effect of day
Test Day     
  Day 1  Day 6  F  p 
Stanford Sleepiness  0.79  −0.07 7.82  0.007
Buschke Selective Reminding       
 Immediate  Recall  −2.80 0.34  2.68  0.108
 Long  Term  Storage  (LTS)  −7.63  −0.21 4.73  0.035
 Delayed  Recall  −1.80  −0.02 8.11  0.006
Motor Screen Latency  −37.90  −46.17 0.07  0.798
RVP      
 A'  0.00  0.02  8.27  0.006
 Mean  Latency  2.21  −38.84 12.22 0.001
Simple Reaction Time       
 Reaction  Time  −13.07  −17.07 0.84  0.364
 Movement  Time  −17.06  −23.50 0.16  0.690
Choice Reaction Time       
 Reaction  Time  −2.13  −5.05 0.20  0.657
 Movement  Time  −5.93  −7.26 0.00  0.959
Digit Symbol Test  0.07  4.82  9.96  0.003
Note: All scores have been adjusted with age as a covariate.
Table 2 Change from baseline for all subjects: main effect of dose
Test  Dose     
  0.15 mg  0.30 mg  0.60 mg  F  p 
Stanford Sleepiness  −0.14 0.94  0.27  4.20  0.021
Buschke Selective Reminding         
 Immediate  Recall  2.47  −1.45  −4.70 4.68  0.014
 Long  Term  Storage  (LTS)  3.70  −6.00  −9.46 5.34  0.008
 Delayed  Recall  −0.18  −0.43  −2.10 3.71  0.032
Motor Screen Latency  −80.61  −43.73  −1.77 2.01  0.145
RVP        
 A'  0.01  0.00  0.01  1.55  0.223
 Mean  Latency  −11.98  −23.07  −19.90 0.31  0.731
Simple Reaction Time         
 Reaction  Time  −17.56  −18.81  −8.85 2.06  0.138
 Movement  Time  −44.60  −9.22  −7.02 2.30  0.111
Choice Reaction Time         
 Reaction  Time  −3.13  −9.97 2.32  1.18  0.315
 Movement  Time  −53.22 26.86  6.57  3.46  0.039
Digit Symbol Test  4.22  2.76  0.35  2.25  0.116
Note: All scores have been adjusted with age as a covariate.Neuropsychiatric Disease and Treatment 2008:4(1) 281
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Analyses of this variable demonstrated no signiﬁ  cant main 
effects for Day or Dose.
Information processing efﬁ  ciency/
sustained attention
For the A' score of the Rapid Visual Information Processing 
task, there was a main effect for Day (F = 8.27, p   0.006) 
and no effect for Dose. The increase in A' was signiﬁ  cantly 
higher on Day 6 as compared to Day 1 (F = 8.27, p = 0.006), 
although the magnitude of this effect was small. Mean 
Latency analyses demonstrated a main effect of Day 
(F = 12.22, p = 0.001) and no effect of Dose. Mean latencies 
increased slightly on Day 1, but declined on Day 6.
Simple/complex attention
For the Simple Reaction Time measures, there was no effect 
of Day or Dose on Reaction Time or Movement Time. For 
the Choice Reaction Time measures, there was no effect of 
DAY or DOSE on Reaction Time, but there was a main effect 
of DOSE on Movement Time (F = 3.46, p = 0.39). Post-hoc 
comparisons of the effect of DOSE on Choice Reaction Time, 
Movement Time demonstrated that individuals in the Low 
Dose condition had faster Movement Time scores relative 
to baseline whereas subjects in the Medium Dose condition 
had slower Movement Time scores relative to baseline mea-
sures. The small increase in Movement Time for the High 
Dose condition was not signiﬁ  cant (p   0.06). A review of 
Table 2 reveals that the magnitude of the changes evident 
for the Dose effect (26–54 milliseconds) are relatively small 
in comparison to the standard deviation around the baseline 
mean (393.5 ± 146.9 milliseconds).
Psychomotor problem solving
Digit Symbol analyses revealed a signiﬁ  cant Day effect 
(F = 9.96, p = 0.003) and no effect for Dose. Subjects 
demonstrated signiﬁ  cantly improved test scores on Day 6 as 
compared to Day 1. An inspection of the data demonstrates 
that on Day 1 there was essentially no change from baseline 
performance. On Day 6, however, there was an increase 
in performance as compared to baseline, though this mean 
change did not exceed ﬁ  ve points. This difference represents 
approximately 1.5 standard deviations from the baseline 
mean (88.9 ±10.8).
Discussion
Overall, the results of this study suggest that subjects 
experienced very mild and transient negative effects on 
neuropsychological functioning when taking pagoclone, 
particularly at Day 1 and at doses above 0.15 mg. Although 
statistically signiﬁ  cant, these ﬁ  ndings were not generally 
clinically meaningful and most had dissipated by the second 
day (Day 6) of testing.
Speciﬁ  cally, with regard to dose of pagoclone, decre-
ments in performance from baseline in learning and memory 
scores were generally greater for the high dose as compared 
with either the low or medium doses. For self-report of 
fatigue and the CRT movement time, the differences in the 
change scores from baseline were only noted for the medium 
as compared with the low dose. An inspection of the change 
scores generally suggested that speed and fatigue improved 
on the low dose, but declined on the medium dose, and to a 
lesser degree on the high dose. The clinical signiﬁ  cance of 
these changes, however, must be considered. Across dose 
levels, the largest mean change did not exceed one point on 
the sleepiness scale, below what would be typically viewed as 
a clinically meaningful change on this measure. In addition, 
although statistically signiﬁ  cant differences were evident in 
change scores on the Movement Time measure, an evaluation 
of mean scores and standard deviations for baseline suggest 
that the changes were not outside of expectation for basic 
test-retest variability.
These findings suggest that sedation effects with 
increased dose of pagoclone appear to be only very mild in 
nature, particularly since effects were not evident on more 
objective measures of motor speed and attention. Learning 
and memory scores, however, did suggest a fairly consistent 
pattern of somewhat lowered performance for the higher dose 
level, though additional analyses demonstrated that these 
changes were reasonably low in magnitude and no longer 
evident during testing on Day 6.
With respect to the day of testing, change scores from 
baseline reﬂ  ected increased self-report of sleepiness and 
slower speed of information processing, along with poorer 
long term storage, on the ﬁ  rst, as compared to the sixth, day 
of testing regardless of dose. Consistent with research dem-
onstrating temporary memory impairments with the use of 
benzodiazepines (eg, Roth et al 1984; Lister 1985; Curran 
1986; Ghoneim and Mewaldt 1990; Greenblatt et al 1991; 
Greenblatt 1992), these ﬁ  ndings are suggestive of mild and 
short-lived sedation effects for pagoclone, regardless of Dose. 
In comparison to the decrements in select areas of neuropsy-
chological performance noted on Day 1, improvements in 
performance were seen on Day 6 for psychomotor problem 
solving and target detection. These lowered performances 
on Day 1 followed by improvements on Day 6 on multiple 
tasks could reﬂ  ect increased efﬁ  ciency related to repeated Neuropsychiatric Disease and Treatment 2008:4(1) 282
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task performance, though this is unlikely given three practices 
prior to baseline. The fact that lowered performance on sev-
eral tasks on Day 1 did not signiﬁ  cantly vary with drug dose 
raises the possibility of factors other than a direct effect of 
the pagoclone. It is possible, for example, that Day 1 effects 
may have been related to environmental or random factors 
other than pagoclone administration. However, the poorer 
performance on Day 1 was consistent across all three dosing 
periods suggesting a drug effect.
Unfortunately, the lack of a placebo control group, use of 
open label, small sample size and relatively large number of 
statistical analyses limit the overall conclusions that can be 
drawn from this preliminary study. The results do suggest, 
however, that across the six days of the study, behavioral 
toxicity of pagoclone was not a concern at these doses. Future 
research in larger groups of individuals and over longer 
periods of time is needed.
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